Quince therapeutics announces first patient dosed in phase 3 clinical trial of erydex for the treatment of ataxia-telangiectasia

South san francisco, calif.--(business wire)---- $qncx--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that the first patient has been dosed in the company's phase 3 neat (neurologic effects of erydex on subjects with a-t) clinical trial to evaluate the neurological effects of erydex in patients with ataxia-telangiectasia (a-t).
QNCX Ratings Summary
QNCX Quant Ranking